Advances in gastro retentive drug-delivery systems

Expert Opinion on Drug Delivery

Volumn 8, Issue 9, 2011, Pages 1189-1203

  Prinderre, Pascal ^a   Sauzet, Christophe ^a   Fuxen, Claus ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Siegfried Ltd   (Switzerland)

Author keywords

Drug delivery systems; Fixed dose combinations; Floating; Gastroretentive; Multiple units

Indexed keywords

ACICLOVIR; ALFUZOSIN; AMOXICILLIN; ANTACID AGENT; BENSERAZIDE PLUS LEVODOPA; CALCIUM ALGINATE; CARBOMER; CARBOXYMETHYLCELLULOSE; CARVEDILOL; CELLULOSE ACETATE; CHITOSAN; CIPROFLOXACIN; DIAZEPAM; ETHYL CELLULOSE; EUDRAGIT; FLUOROURACIL; FUROSEMIDE; GABAPENTIN; GAVISCON; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; GRALISE; HYDROXYETHYLCELLULOSE; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; METHYLCELLULOSE; METRONIDAZOLE; POLYMER; TOPALKAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; GELATION; HUMAN; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MAGNETISM; NONHUMAN; REVIEW; STOMACH; TABLET FORMULATION; TECHNOLOGY;

ADMINISTRATION, ORAL; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; FOOD-DRUG INTERACTIONS; GASTRIC EMPTYING; HUMANS; STOMACH; TECHNOLOGY, PHARMACEUTICAL;

EID: 80052088343     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.592828     Document Type: Review

References (112)

1. Kagan L, Hoffman A. Systems for region selective drug delivery in gastrointestinal tract: biopharmaceutical considerations. Expert Opin Drug Deliv 2008;8(6):681-92 (Pubitemid 351998257)
2. Bolton S, Desai S. Floating sustained-release therapeutic compositions. US4814179; 1989
3. Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst 1999;16:571-639 (Pubitemid 30084602)
4. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 1996;136:117-39 (Pubitemid 26199405)
5. Bardonnet PL, Faivrea V, Pugh WJ, et al. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release 2006;111:1-18. (Pubitemid 43289989)
6. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Ther Drug carrier Syst 1998;15(3):243-84 (Pubitemid 28366513)
7. Mayersohn M. In: Banker GS, Rhodes CT, editors, Principles of drug absorption, drugs and the pharmaceutical sciences: modern pharmaceutics. Volume 121. Marcel Dekker, New York; 2002. p. 23-66
8. Russel TL, Berardi RR, Barnett JL, et al. Upper gastrointestinal pH in seventy-nine healthy, elderly, north american man and women. Pharm Res 1993;10:187-96 (Pubitemid 23041729)
9. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Del Rev 2001;46:75-87
10. Bannister LH. Alimentary system. In: PL, editor, Churchill Livingstone. Volume XXXVIII. Williams (ed.) Grays Anatomy, New York; 1995. p. 125-56
11. Minami H, McCallum RW. The physiology and pathophysiology of gastric emptying in humans. Gastroenterology 1984;86:1592-610 (Pubitemid 14147957)
12. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv 2006;3:217-33. (Pubitemid 43338093)
13. Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993;10(2):143-95 (Pubitemid 23198886)
14. Klausner A, Eyala S, Lavy E, et al. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J Control Release 2003;88:117-26 (Pubitemid 36173957)
15. OReilly S, Wilson CG, Hardy JG. The influence of food on the gastric emptying of multiparticulate dosage forms. Int J Pharm 1987;l34:213-16 (Pubitemid 17227498)
16. Sangekar S, Vadino WA, Chaudry I, et al. Evaluation of the effect of food and specific gravity of tablets on gastric retention time. Int J Pharm 1987;35:187-97
17. Khosla R, Feely LC, Davis SS. Gastrointestinal transit of non-disintegrating tablets in fed subjects. Int J Pharm 1989;53:107-17
18. Abrahamsson B, Alpsten M, Hugosson M. Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets. Pharm Res 1993;10:709-14 (Pubitemid 23152317)
19. Singh NB, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000;63:235-59.
20. Hoener B-A, Benet LZ. In: Banker GS, Rhodes CT, editors, Factors influencing drug absorption and drug availability, drugs and the pharmaceutical sciences: modern pharmaceutics. Volume 121. Marcel Dekker, New York; 2002. p. 93-117
21. Dressman JB, Berardi RR, Dermentzoglou LC, et al. Upper gastrointestinal pH in young, healthy men and women. Pharm Res 1990;7:756-61 (Pubitemid 20278376)
22. Kamba M, Seta Y, Kusai A, et al. A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract. Int J Pharm 2000;208:61-70
23. Mojaverian P, Vlasses PH, Kellner PE, et al. Effects of gender, posture and age on gastric residence time of an indigestible solid: Pharmaceutical considerations. Pharm Res 1988;10:639-44 (Pubitemid 18263610)
24. Bennett CE, Hardy JG, Wilson CG. The influence of posture on the gastric emptying of antacid. Int J Pharm 1984;21:341-7 (Pubitemid 14017185)
25. Garg S, Sharma S. Gastroretentive drug delivery systems. Business Briefing: Pharmatech; 2003. p. 160-66
26. Caldwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US4735804; 1988
27. Caldwell LJ, Gardner CR. Drug delivery device which can be retained in the stomach for a controlled period of time. US4758436; 1988
28. Klausner EA, Eyal S, Lavy E, et al. Novel levodopa gastroretntive dosage form: in-vivo evaluation in dogs. J Control Release 2003;88:117-26 (Pubitemid 36173957)
29. Klausner EA, Lavy E, Friedman M, et al. Expandable gastroretentive dosage forms. J Control Release 2003;90:143-62 (Pubitemid 36700451)
30. Berner B, Hou Sui Yuen E. A gastric retained dosage form of gabapentin. US20040903879; 2004
31. Markey M, Shell John W. Berner Bret. WO0132217; 2001
32. Jain SK, Agarwal GP, Jain NK. Porous carrier based on floating granular delivery system of repaglinide. Drug Dev Ind Pharm 2007;33:1-34
33. Jagathesan M. EP1648425; 2004
34. Sauzet C, Claeys-Bruno M, Nicolas M, et al. An innovative floating gastro retentive dosage system: formulation and in vitro evaluation. Int J Pharm 2009;378:23-9.
35. Kawashima Y, Niwa T, Takeuchi H, et al. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci 1992;81:135-40
36. Chaudhari M, Chandwani O, Yelegaonkar R, et al. EP1745775; 2005
37. Timmermans J. Floating hydrophilic matrix dosage forms for oral use: factors controlling their buoyancy and gastric residence capabilities. Ph.D. Thesis. University of Brussels; 1991
38. Clarke GM, Newton JM, Short MB. Comparative gastrointestinal transit of pellet systems of varying density. Int J Pharm 1995;114:1-11 (Pubitemid 24377024)
39. Louie-Helm J, Berner B, Fell R, et al. Parmacokinetics of ciprofloxacin gastric retentive tablets in healthy volunteers. Proc Int Symp Control Release Bioact Mater 2001
40. Rouge N, Allemann E, Gex-Fabry M, et al. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. Pharmaceutica Acta Helvetiae 1998;73:81-7 (Pubitemid 28327969)
41. Simoni P, Cerre C, Cipolla A, et al. Bioavailability study of a new, sinking, enteric-coated ursodeoxycholic acid formulation. Pharmacol Res 1995;31(2):115-18
42. Groning R, Berntgen M, Georgarakis M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Eur J Pharm Biopharm 1998;46:285-91 (Pubitemid 29057675)
43. Groning R, Cloer C, Georgarakis M, et al. Compressed collagen sponges as gastroretentive dosage forms: in vitro and in vivo studies. Eur J Pharm Sci 2007;30:1-6 (Pubitemid 44908920)
44. Kagan L, Lapidotb N, Afargan M, et al. Gastroretentive accordion pill: enhancement of riboflavin bioavailability in humans. J Control Release 2006;113:208-19
45. Curatolo W, Lo J. Gastric retention system for controlled drug release. US19880200801; 1988
46. Sonobe T, Watanabe S. Gastric retention device. JP19890225245; 1989
47. Omidian H, Rocca JG, Park K. Advances in superporous hydrogels. J Control Release 2005;102:3-12 (Pubitemid 40093771)
48. Park H, Park K, Dukjoon K. Preparation and swelling behavior of chitosan-based superporous hydrogels for gastric retention application. J Biomed Mater Res A 2006;76:144-50 (Pubitemid 43075692)
49. Torrado S, Prada P, de la Torre PM, et al. Chitosan-poly(acrylic) acid polyionic complex: in vivo study to demonstrate prolonged gastric retention. Biomaterials 2004;25:917-23 (Pubitemid 37371999)
50. Chen J, Park K. Synthesis of fast swelling, superporous sucrose hydrogels. Carbohydrate Polymers 2000;41:259-68 (Pubitemid 30544750)
51. Chen J, Blevins WE, Park H, et al. Gastric retention properties of superporous hydrogel composites. J Control Release 2000;64:39-51 (Pubitemid 30035306)
52. Dhaliwal S, Jain S, Singh HP, et al. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: In vitro and in vivo evaluation. AAPS J 2008;10:322-30
53. Klausner EA, Lavy E, Barta M, et al. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharmacol Res 2003;20(9):1466-73 (Pubitemid 37164056)
54. Eaimtrakarn S, Prasad YVR, Puthli SP, et al. Possibility of a patch system as a new oral delivery system. Int J Pharm 2003;250:111-17 (Pubitemid 35447941)
55. Lele BS, Hoffman AS. Mucoadhesive drug carriers based on complexes of poly (acrylic acid) and PEGylated drugs having hydrolysable PEG-anhydridedrug linkages. J Control Release 2000;69:237-48
56. Chun MK, Sah H, Choi HK. Preparation of mucoadhesive microspheres containing antimicrobial agents for eradication of H. pylori. Int J Pharm 2005;297:172-9 (Pubitemid 40720277)
57. Timmermans J, Van Gansbeke B, Moes AJ. Assessing by gamma scintigraphy the in vivo buoyancy of dosage forms having known size and floating force profiles as a function of time. Proc APGI Int Conf Pharm Technol 1989;1:42-51
58. Timmermans J, Moes AJ. How well do floating dosage forms float? Int J Pharm 1990;62:207-16 (Pubitemid 20261790)
59. Timmermans J, Moes AJ. Measuring the resultant-weight of an immersed test material: I. Validation of an apparatus and a method dedicated to pharmaceutical applications. Acta Pharm Technol 1990;36:171-5 (Pubitemid 20331065)
60. Timmermans J, Moes AJ. Measuring the resultant-weight of an immersed test material: II. Examples of kinetic determination applied to monolithic dosage forms. Acta Pharm technol 1990;36:176-80 (Pubitemid 20331066)
61. Steingoetter A, Weishaupt D, Kunz P, et al. Magnetic resonance imaging for the in vivo evaluation of gastric-retentive tablets. Pharm Res 2003;20:2001-7 (Pubitemid 38005532)
62. Naresh T, Himadri S. Orally administered controlled drug delivery system providing temporal and spatial control. WO0015198; 2000
63. Afargan M, Kirmayer D. Gastro-Retentive diagnostic assemblies. WO2006072948; 2006
64. Baumgartner S, Kristl J, Vrecer F, et al. Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int J Pharm 2000;195:125-34
65. Washington N, Washington C, Wilson CG, et al. What is "Liquid Gaviscon"? a comparison of four international formulations. Int J Pharm 1986;34(1-2):105-9 (Pubitemid 17216783)
66. Elkheshen SA, Yassin AEB, Alsuwayeh S, et al. In vitro and in vivo evaluation of floating controlled release dosage forms of verapamil hydrochloride. Pharmazeutische Ind 2004;66:1364-72 (Pubitemid 39611263)
67. Meka L, Kesavan B, Kalamata VN, et al. Design and evaluation of polymeric coated minitablets as multiple unit gastroretentive floating drug delivery systems for furosemide. J Pharm Sci 2009;98:2122-32
68. Krogel I, Bodmeier R. Floating or pulsatile drug delivery systems based on coated effervescent cores. Int J Pharm 1999;187:175-84 (Pubitemid 29443897)
69. Kawashiwa Y, Niwa T, Takeuchi H, et al. Preparation of multiple unit hollow microspheres (microballoons) with acrylic resin containing tranilast and their drug release characteristics (in vitro) and floating behavior (in vivo). J Control Release 1991;16:279-90
70. Ichigawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage system. Preparation and in vitro evaluation of floating and sustained-release characteristics. J Pharm Sci 1991;80:1062-6
71. Sungthongjeen S, Paeratakul O, Limmatvapirat S, et al. Preparation and in vitro evaluation of a multiple-unit floating drug delivery system based on gas formation technique. Int J Pharm 2006;324:136-43 (Pubitemid 44528911)
72. Hamdani J, Moes AJ, Amighi K. Development and in vitro evaluation of a novel floating multiple unit dosage form obtained by melt pelletization. Int J Pharm 2006;322:96-103 (Pubitemid 44339598)
73. Fukuda M, Peppas NA, McGinity JW. Floating hot-melt extruded tablets for gastroretentive controlled drug release system. J Control Release 2006;115:121-9 (Pubitemid 44537498)
74. Atyabi F, Sharma HL, Mohammad HAH, et al. Controlled drug release from coated floating ion exchange resin beads. J Control Release 1996;42:25-8 (Pubitemid 26297872)
75. Todd RS, Fryers GR. Cholestyramine compositions and method for treating biliary gastritis. US4172120; 1979
76. Seth PR, Tossounian J. The hydrodynamically balanced system (HBSTM): a novel drug delivery system for oral use. Drug Dev Ind Pharm 1984;10:313-39 (Pubitemid 14137879)
77. Sheth PR, Tossounian JL. Sustained release pharmaceutical capsules. US4126672; 1978
78. Sheth PR, Tossounian JL. Sustained release tablet formulations. US4140755; 1979
79. Sheth PR, Tossounian JL. Novel sustained release tablet formulations. US4167558; 1979
80. Ushimaru K. Pharmaceutical preparations and a method of manufacturing them. US4702918; 1987
81. Mitra SB. Sustained release oral medicinal delivery device. US4451260; 1984
82. Losi E, Bettinia R, Santi P, et al. Assemblage of novel release modules for the development of adaptable drug delivery systems. J Control Release 2006;11(1-2):212-18. (Pubitemid 43290010)
83. Strusi OL, Sonvico F, Bettini R, et al. Module assemblage technology for floating systems: in vitro flotation and in vivo gastro-retention. J Control Release 2008;129:88-92
84. Casas M, Strusi OL, Jimenez-Castellanos R, et al. Tapioca starch graft copolymers and Dome Matrix- modules II. Effect of modules assemblage on Riboflavin release kinetics. Eur J Pharm Biopharm 2011;77:111-15
85. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm 2002;241:279-92 (Pubitemid 34718029)
86. Streubel A, Siepmann J, Bodmeier R. Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles. J Microencapsul 2003;20:329-47 (Pubitemid 36621475)
87. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci 2003;18:37-45 (Pubitemid 36120553)
88. Sato Y, Kawashima Y, Takeuchi H, et al. In vivo evaluation of riboflavin-containing microballoons for floating controlled drug delivery system in healthy human volunteers. J Control Release 2003;93:39-47 (Pubitemid 37346267)
89. Soppimath KS, Kulkarni AR, Rudzinski WE, et al. Microspheres as floating drug-delivery systems to increase gastric retention of drugs. Drug Metabolism Review 2001;33:149-60 (Pubitemid 32703254)
90. Kawashima Y, Niwa T, Takeuchi H, et al. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci 1992;81:135-40
91. Sato Y, Kawashima Y, Takeuchi H, et al. In vitro and in vivo evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans. Int J Pharm. 2004;275(1-2):97-107 (Pubitemid 38481523)
92. Choudhury PK, Kar M, Chauhan CS. Cellulose acetate microspheres as floating depot system to increase gastric retention of antidiabetic drug: formulation, characteristics and in vitro - in vivo evaluation. Drug Dev Ind Pharm 2008;34:349-54 (Pubitemid 351519667)
93. Whitehead L, Fell JT, Collett JH, et al. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release 1998;55:3-12 (Pubitemid 28477559)
94. Vanderbist F, Baudier P, Deboeck A, et al. WO2007106960
95. Shishu GN, Aggarwal N. Stomach-specific drug delivery of 5-fluorouracil using floating alginate beads. AAPS Pharm Sci Tech 2007;8: article 48
96. Badve SS, Sher P, Korde A, et al. Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery. Eur J Pharm Biopharm 2007;65:85-9
97. Baljit S, Vikrant S, Dimpal C. Gastroretentive floating sterculia-alginate beads for use in antiulcer drug delivery. Chem Eng Res Des 2010;88:997-1012
98. Ishak RA, Awad GA, Mortada ND, et al. Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy. J Control Release 2007;119:207-14 (Pubitemid 46754505)
99. Prinderre P, Sauzet C. Process for making gastroretentive dosage forms. EP08290529
100. Rajinikanth PS, Balasubramaniam J, Mishra B. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. Int J Pharm 2007;335(1-2):114-22 (Pubitemid 46482869)
101. Umamaheshwari RB, Jain S, Tripathi PK, et al. Floating bioadhesive microspheres containing acetohydroxamic acid for clearance of Helicobacter pylori. Drug Deliv 2002;9:223-31 (Pubitemid 35397024)
102. Jimenez-Castellanos MR, Ziaa H, Rhodes CT, et al. Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm 1994;105:65-70 (Pubitemid 24087674)
103. Chavanpatil M, Jain P, Chaudhari S, et al. Development of sustained- release gastroretentive drug delivery system for ofloxacin: In vitro and in vivo evaluation. Int J Pharm 2005;304:178-84 (Pubitemid 41427660)
104. Tadros MI. Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: development, optimization and in vitro-in vivo evaluation in healthy human volunteers. Eur J Pharm Biopharm 2010;74:332-9
105. Hu L, Li L, Yang X, et al. Floating matrix dosage form for dextromethorphan hydrobromide based on gas forming technique: In vitro and in vivo evaluation in healthy volunteers. Eur J Pharm Sci 2011;42:99-105
106. Desai S, Bolton SA. Floating controlled-release drug delivery systems: in vitro-in vivo evaluation. Pharm Res 1993;10:1321-5 (Pubitemid 23261833)
107. Chien-Hsuan H. Gastroretentive drug delivery system: Acuform- Technology, AAPS Modified Release Focus Group; 2010. p. 2-4
108. Tsabari M, Balshey A, Yofe E. US2009304753; 2009
109. Talwar N, Sen H, Staniforth JN. Orally administered controlled drug delivery system providing temporal and spatial control. US6261601; 2001
110. Bhachaland DN, Rupsinh ZY. WO2005101983; 2005
111. IntecPharma. Available from: http://www.intecpharma.com/
112. Hascicek C, Rossi A, Colombo P, et al. Assemblage of drug release modules: effect of module shape and position in the assembled system on floating behavior and release rate. Eur J Pharm Biopharm 2011;77:116-21